- Home
- HQL vs CLLS Comparison
HQL vs CLLS Comparison
Compare HQL & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQL | CLLS |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.1M | 438.4M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | HQL | CLLS |
|---|---|---|
| Price | $17.16 | $3.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 120.9K | 40.7K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $11.34 | $1.10 |
| 52 Week High | $14.37 | $5.48 |
Technical Indicators
Market Signals| Indicator | HQL | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 32.21 |
| Support Level | $16.80 | $4.04 |
| Resistance Level | $17.40 | $3.95 |
| Average True Range (ATR) | 0.31 | 0.21 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 70.43 | 0.00 |
Price Performance
Historical ComparisonAbout HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.